ANGIODYNAMICS INC — Director's Dealing 2023

Jul 21, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2023-07-19

Reporting Person: Campbell Chad Thomas (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-07-19	Common Stock	A	11384	—	Acquired	48263	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-07-19	Performance Right	$	A	22768	Acquired		Common Stock (22768)	Direct
2023-07-19	Non-Qualified Stock Option (right to buy)	$8.92	A	23561	Acquired	2033-07-19	Common Stock (23561)	Direct

Footnotes

F1: The acquisition of 11,384 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 11,384 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.

F2: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F3: These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.